Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma

Launched by AZIENDA USL REGGIO EMILIA - IRCCS · Feb 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how to better understand and treat Classical Hodgkin Lymphoma (cHL), a type of cancer that primarily affects young adults and is generally treatable. The researchers aim to improve how doctors assess the disease by looking at the genetic makeup of tumors and using advanced imaging techniques. They believe that by analyzing the DNA and other features of the tumor at diagnosis and during treatment, they can identify patients who are at a higher risk of treatment failure. This could lead to more personalized treatment plans that effectively control the disease while minimizing side effects.

To participate in this study, you must be over 18 years old and have a confirmed diagnosis of cHL, either newly diagnosed or recurrent. You will need to provide consent and have certain tests and samples taken, such as blood tests and tumor biopsies. Throughout the trial, participants can expect regular follow-ups and additional tests to monitor their condition. This research is important because it could help doctors tailor treatments specifically to each patient’s needs, ultimately aiming to improve cure rates and quality of life for those battling Hodgkin Lymphoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \>18 anni
• • Written informed consent signed
• • Cohort A
• • Age \>18 years
• • Histologically confirmed diagnosis of relapsed/refractory classical Hodgkin lymphoma identified during induction or follow-up
• • Available formalin-fixed, paraffin-embedded (FFPE) biopsy at diagnosis and at the time of progression/relapse
• • Available plasma sample at progression (before the beginning of salvage therapy)
• • Available FDG-PET evaluation at study enrollment
• • Available clinical, laboratory, and radiologic data at diagnosis and relapse
• • Cohort B
• • Diagnosis of classical Hodgkin lymphoma
• • Completion of first-line standard systemic treatment (chemotherapy-based or chemoradiotherapy combined modality)
• • Available plasma sample at the end of treatment (at least 30 days from the last chemotherapy)
• • Available FFPE biopsy at diagnosis
• • No further treatment planned
• • Available clinical, laboratory, and radiologic data at diagnosis and response evaluation
• • Patient's willingness to undergo 6 months follow-up plasma sample collection and to attend regular follow-up
• • Cohort C
• • Histologically confirmed diagnosis of classical Hodgkin lymphoma
• • Standard treatment as per available guidelines (e.g., ESMO guidelines)
• • Available treatment data, response, and follow-up data
• • Available FFPE biopsy at diagnosis
• • Available FDG-PET evaluation at study enrollment
• Exclusion Criteria:
• • Patients with nodular lymphocyte predominant Hodgkin lymphoma are not eligible; all other subtypes including nodular sclerosis, lymphocyte-depleted, lymphocyte-rich, and mixed cellularity Hodgkin lymphoma may be enrolled.
• • Active HIV, HBV, HCV viral infection
• • Concomitant neoplasm not treated with a curative aim